Melanotan II
A non-selective melanocortin receptor agonist that induces skin tanning, appetite suppression, and sexual arousal, but carries significant safety concerns.
Also known as: MT-2, MT-II, Melanotan 2
Regulatory Status
Classification date: 2024-06-01
Compounding: Not currently available for compounding
Evidence Summary
How It Works
Melanotan II is a cyclic heptapeptide analog of alpha-MSH that non-selectively activates melanocortin receptors MC1R through MC5R. MC1R activation stimulates melanogenesis (tanning without UV exposure), MC4R activation produces sexual arousal and suppresses appetite, and MC3R activation may affect energy homeostasis. Its broad receptor activity is responsible for both its diverse effects and its significant side-effect profile. Unlike the more selective PT-141 (bremelanotide), Melanotan II has never been developed as a pharmaceutical product.
Common Applications
Safety & Considerations
Significant safety concerns exist. Common side effects include severe nausea, facial flushing, fatigue, and involuntary erections. Serious risks include melanocyte activation that could theoretically promote melanoma development, hypertension, and darkening/changes to existing moles. Unregulated products have had contamination issues. Has never undergone formal clinical development for any indication. Not recommended due to availability of safer, more selective alternatives.
Regulatory classifications can change rapidly. The information shown here was last verified on 2024-06-01. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.